StockData

Castle Biosciences vs Fulgent Genetics

CSTL and FLGT side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CSTL and FLGT compare

Castle Biosciences is the larger company, worth 1.5 times as much as Fulgent Genetics ($1.0B against $666M).

Castle Biosciences grew revenue faster over the last twelve months (9.8% versus 6.8% for Fulgent Genetics).

Castle Biosciences keeps more of each dollar of sales as profit, with a net margin of −6.1% compared with −26.0% at Fulgent Genetics.

Castle Biosciences scores higher on the StockData Score (11 against 7 for Fulgent Genetics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCSTLFLGT
Size and price
Market cap$1.0B$666M
Share price$32.98$24.21
Change, 1 year−1.4%−16.8%
Change, 5 years−23.5%−75.2%
Beta (5Y)0.680.49
Employees8831,300
StockData Score
Total score11 (better)7
Valuation score23 (better)
Growth score2 (better)0
Performance score3 (better)1
Health score4 (better)3
Dividend score00
Valuation
P/S2.7×2.1× (better)
P/B2.1×0.7× (better)
P/FCF254×–
FCF yield0.39% (better)−15.6%
Fair value$34.22$45.28
Margin of safety3.6%46.5% (better)
Growth
Revenue growth (TTM)9.8% (better)6.8%
Revenue growth, 5Y average40.6% (better)−5.2%
Profitability
Gross margin77.1% (better)35.6%
Operating margin−7.4% (better)−37.7%
Net margin−6.1% (better)−26.0%
FCF margin1.1% (better)−32.0%
Return on equity−4.9% (better)−8.0%
Return on invested capital−11.1%−10.9% (better)
Financial health
Debt / equity0.020.00 (better)
Interest coverage−51.2× (better)−1019.0×
Current ratio5.286.34 (better)
Altman Z-score6.49 (better)5.25
Piotroski F-score44
Dividends and buybacks
Dividend yield0.00%–
Years of dividend growth0–
Buyback yield–9.6%
Shareholder yield0.00%9.6% (better)
Ownership
Held by institutions89.5%57.0%
Held by insiders1.9%39.5%
Insider net buying, 12 months−$18.4M−$286K (better)
Short interest, % of float7.0%12.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.